-
Product Insights
Acquired Gene or Chromosome Alterations Pipeline by Development Stages, Segments, Countries, Regulatory Path and Key Companies
Acquired Gene or Chromosome Alterations Pipeline Market Report Overview Acquired Gene or Chromosome Alterations are reagents employed for genetic testing to detect cancer-causing or related alterations. The Acquired Gene or Chromosome Alterations pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated...
-
Sector Analysis
Batten Disease (BD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Batten Disease (BD) Marketed and Pipeline Drugs Report Overview Batten disease is also known as neuronal ceroid lipofuscinosis (NCL) and refers to a cluster of hereditary nervous system disorders that typically manifest in childhood. The diverse forms of the disease are categorized based on the gene responsible for the disorder. Due to the varying gene mutations that can cause the disease, the severity of symptoms and their progression rates differ. Symptoms typically include progressive vision loss leading to blindness, seizures,...
-
Company Profile
Norwegian Cruise Line Holdings Ltd – Company Profile
Norwegian Cruise Line Holdings Ltd (NCLH), formerly NCL Corp Ltd, is an operator of cruise lines. It provides cruises ranging from one week to three weeks. The company offers a distinctive style of cruising called Freestyle Cruising, which provides guests the freedom and flexibility of a resort-style atmosphere. NCLH also provides travelers with cruise itineraries in North America (including Alaska, Hawaii, and Mexico), Central America, Bermuda, the Caribbean, Europe, the Bahamas, Africa, Scandinavia, the Mediterranean, and the Baltic. The company...
Add to Basket -
Sector Analysis
Hepatocellular Carcinoma – Opportunity Analysis and Forecasts to 2029
The hepatocellular carcinoma (HCC) market is expected to grow from $1.4bn in 2019 to $5.5bn in 2029 in the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 14.5%. The significant growth in the therapy market is driven by implementing new strategies such as developing combinations of therapies with different mechanism of actions, label expansion of marketed therapies for HCC into earlier lines of therapy, and label expansion of drugs approved in other indications into HCC. Mandana...